id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-342143-un14oynk	Fernández-Díaz, Eva	COVID-19 and multiple sclerosis: A description of two cases on alemtuzumab	2020-07-17		.txt	text/plain	1614	102	55	Conclusion: In selected patients (young, without comorbidities, and with high activity), MS itself could be more dangerous than COVID-19, so we should consider continuing MS treatment as previously planned, including alemtuzumab. Conclusion: In selected patients (young, without comorbidities, and with high activity), MS itself could be more dangerous than COVID-19, so we should consider continuing MS treatment as previously planned, including alemtuzumab. Therefore, alemtuzumab carries a theoretical high risk of developing COVID-19 if the infection occurs before immune reconstitution and the general recommendation is postponing infusions until the pandemic is controlled (Brownlee et al., 2020; Costa-Frossard França et al., 2020; Giovannoni et al., 2020) . Alemtuzumab in multiple sclerosis during the COVID-19 pandemic: A mild uncomplicated infection despite intense immunosuppression Mild COVID-19 infection in a patient with multiple sclerosis and severe depletion of T-lymphocyte subsets due to alemtuzumab Potential COVID-19 infection in patients with severe multiple sclerosis treated with alemtuzumab Temporal evolution of immune cells populations in our two MS patients who developed COVID-19 under alemtuzumab treatment across disease stages.	./cache/cord-342143-un14oynk.txt	./txt/cord-342143-un14oynk.txt